SICAM-1 AS A SERUM MARKER FOR FOLLOW-UP OF PULMONARY TUBERCULOSIS THERAPY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

VALI ELAHPOUR AMIRI M.; MANSOURI S.D.; SHEKARABI M.; MIRSAEIDI SEYED MAHDI; ZAHIRIFARD S.; KAZEMPOUR DIZAJI M.; TABARSI P.; HALVANI A.A.H.; TABATABAEI S.J.; MASJEDI M.R.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: TANAFFOS Year:2004 | Volume:3 | Issue:11 Page(s): 15-54

Download Full-Text

View:

388

Download:

130

Cites:

Information Journal Paper

Title

SICAM-1 AS A SERUM MARKER FOR FOLLOW-UP OF PULMONARY TUBERCULOSIS THERAPY

Author(s)

Keywords

TUBERCULOSIS (TB)

SICAM-1

SERUM MARKER

THERAPY

Abstract

Background: Tuberculosis (TB) is one of the commonest infectious diseases of our era; it is the second cause of death due to infectious diseases after AIDS. Studies have shown the significant effect of leukocyte integrins such as LFA-1and ICAM-1 on the function of macrophages against TB bacilli; increasing their activity during the process of TB infection.The objective of this research is to evaluate the changes observed in serum levels of SICAM-1 in pulmonary TB patients that had received treatment.Materials and Methods: All new pulmonary TB cases that had not received any treatment ,did not suffer from any kind of co-existing or underlying disorders such as hepatitis, sarcoidosis , lung cancer, HBV, HCV and HIV infections, chronic renal failure, cirrhosis, malnutrition, collagen vascular disorders and had not consumed immunosuppressive agents, were enrolled in this study. The SICAM-1 levels of the cases were measured by ELISA method before and 2 months after treatment with standard anti-TB drugs (Isoniazid, Rifampin, Ethambutol and Pyrazinamide) at the same time. T-test was used to compare the two sets of values of SICAM-1 levels before and 2 months after THERAPY.Results: A total of 28 patients; 23 (82.1%) male and 5(17.9%) female cases were enlisted. Meanwhile, 50% of the patients were Iranian and the remaining had Afghan nationality. All of them were sputum smear and culture positive for Mycobacterium tuberculosis. Regarding the extent of pulmonary involvement as shown on lung CT-Scan, 68% demonstrated diffuse pulmonary involvement. The mean SICAM-1 level before the initiation of treatment was 554.17 ± 202.85 ng/ml. Considering age , sex ratio, ESR level, PPD test and severity of lung involvement, the SICAM-1 levels did not show any significant differences in different groups of patients. Among the patients enrolled in the study we were able to follow the seventeen patients (61%) who completed 2 months of treatment. The mean level of SICAM-1 before and after treatment in these patients were 573.9 ±204.4 and 481.2 ± 103.2 ng/ml, respectively (P<0.05).Conclusion: SICAM-1 is considered as one of the inflammatory mediators that undergoes fluctuations during TB disease; its level is very much related to the extent of lung involvement. Since the level of this marker declines after THERAPY, it could be used as a "Serum marker "in evaluating the therapeutic response observed during the follow- up.Abbreviations: SICAM: Soluble Intercellular Adhesion Molecule, ICAM: Intercellular Adhesion Molecule, LFA: Leukocyte Function Antigen.

Cites

No record.

References

Cite

APA: Copy

VALI ELAHPOUR AMIRI, M., MANSOURI, S.D., SHEKARABI, M., MIRSAEIDI, SEYED MAHDI, ZAHIRIFARD, S., KAZEMPOUR DIZAJI, M., TABARSI, P., HALVANI, A.A.H., TABATABAEI, S.J., & MASJEDI, M.R.. (2004). SICAM-1 AS A SERUM MARKER FOR FOLLOW-UP OF PULMONARY TUBERCULOSIS THERAPY. TANAFFOS, 3(11), 15-54. SID. https://sid.ir/paper/542186/en

Vancouver: Copy

VALI ELAHPOUR AMIRI M., MANSOURI S.D., SHEKARABI M., MIRSAEIDI SEYED MAHDI, ZAHIRIFARD S., KAZEMPOUR DIZAJI M., TABARSI P., HALVANI A.A.H., TABATABAEI S.J., MASJEDI M.R.. SICAM-1 AS A SERUM MARKER FOR FOLLOW-UP OF PULMONARY TUBERCULOSIS THERAPY. TANAFFOS[Internet]. 2004;3(11):15-54. Available from: https://sid.ir/paper/542186/en

IEEE: Copy

M. VALI ELAHPOUR AMIRI, S.D. MANSOURI, M. SHEKARABI, SEYED MAHDI MIRSAEIDI, S. ZAHIRIFARD, M. KAZEMPOUR DIZAJI, P. TABARSI, A.A.H. HALVANI, S.J. TABATABAEI, and M.R. MASJEDI, “SICAM-1 AS A SERUM MARKER FOR FOLLOW-UP OF PULMONARY TUBERCULOSIS THERAPY,” TANAFFOS, vol. 3, no. 11, pp. 15–54, 2004, [Online]. Available: https://sid.ir/paper/542186/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops